<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perioperative management of adults with sickle cell disease or thalassemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perioperative management of adults with sickle cell disease or thalassemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Perioperative management of adults with sickle cell disease or thalassemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ian J Welsby, BSc, MBBS, FRCA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele Heath, LP, CCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Strouse, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2546476248"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with hemoglobinopathies have unique risks for complications during or after surgical procedures, especially cardiac surgery with cardiopulmonary bypass. Management encompasses the perioperative period. In addition, patients with sickle cell disease may require complex postoperative strategies for pain control due to chronic opioid use and opioid tolerance.</p><p>This topic discusses perioperative management of adults with common hemoglobinopathies such as sickle cell disease, sickle cell trait, or thalassemia.</p><p>Separate topics discuss general aspects of management:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell disease</strong> – (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a> and  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell</strong> <strong>trait</strong> – (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia</strong> – (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hemoglobinopathies</strong> – (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a>.)</p><p></p><p class="headingAnchor" id="H3748971557"><span class="h1">SICKLE CELL DISEASE</span><span class="headingEndMark"> — </span>Sickle cell disease (SCD) includes all hemoglobinopathies with the sickle cell variant on one beta globin allele and another beta globin variant on the other allele.</p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell anemia (homozygous hemoglobin SS, Hb SS)</p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell-beta thalassemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin SC disease</p><p class="bulletIndent1"><span class="glyph">●</span>Other combinations with hemoglobin S, such as Hb D or Hb E</p><p></p><p>Hospitals that have a dedicated SCD program will ensure routine hematology involvement in perioperative planning. However, only a very small percentage of hospitals have such programs.</p><p class="headingAnchor" id="H3975237389"><span class="h2">Preoperative assessment and optimization</span><span class="headingEndMark"> — </span>If SCD is identified before elective major surgery, management of perioperative care should be in a center with a multidisciplinary team that includes hematology, anesthesiology, and surgery team members. For cardiac surgical procedures requiring cardiopulmonary bypass (CPB), perfusion team members should also participate. Considerations include disease severity, medications, baseline hemoglobin, percent abnormal hemoglobin (Hb S or other variant[s]), transfusion history, prior surgical complications, and the planned procedure.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Review of history </strong>–<strong> </strong>In all cases, a thorough preoperative review of the patient’s clinical history and manifestations of SCD is necessary to determine perioperative risk factors (see  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a>). Manifestations of SCD that may require specialized preoperative optimization and intraoperative management are discussed in separate topics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiomyopathy with diastolic dysfunction – (See  <a class="medical medical_review" href="/d/html/105407.html" rel="external">"Perioperative management of heart failure in patients undergoing noncardiac surgery"</a> and  <a class="medical medical_review" href="/d/html/91654.html" rel="external">"Intraoperative management for noncardiac surgery in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary hypertension – (See  <a class="medical medical_review" href="/d/html/94362.html" rel="external">"Anesthesia for noncardiac surgery in patients with pulmonary hypertension or right heart failure"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior myocardial infarction or stroke – (See  <a class="medical medical_review" href="/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a> and  <a class="medical medical_review" href="/d/html/90616.html" rel="external">"Anesthesia for noncardiac surgery in patients with ischemic heart disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asthma or other chronic lung disease – (See  <a class="medical medical_review" href="/d/html/7121.html" rel="external">"Overview of the pulmonary complications of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney dysfunction – (See  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Prevention and management (sickle nephropathy)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease – (See  <a class="medical medical_review" href="/d/html/91242.html" rel="external">"Anesthesia for the patient with liver disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recent acute chest syndrome, defined as a new radiodensity on chest imaging with fever and/or respiratory symptoms in a patient with SCD. Non-emergency surgery is deferred until full recovery – (See  <a class="medical medical_review" href="/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior venous thromboembolism with ongoing anticoagulation. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydration status </strong>– Individuals with SCD are at increased risk of volume depletion while not taking in oral fluids perioperatively, as they usually develop urinary concentrating defects as young children. For this reason, we continue oral clear liquids until two hours before surgery, as noted in standard fasting guidelines  (<a class="graphic graphic_table graphicRef94641" href="/d/graphic/94641.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/d/html/15698.html" rel="external">"Preoperative fasting in adults"</a>). For patients who are receiving "nothing per os" (NPO) for longer periods, we implement hydration with intravenous fluids (typically 5% dextrose with 0.45% NaCl) unless the case is scheduled as first in the morning. (See  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Prevention and management (sickle nephropathy)'</a> and  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Management during hospitalization'</a>.)</p><p></p><p class="headingAnchor" id="H2443725685"><span class="h2">Decisions regarding prophylactic preoperative transfusion</span></p><p class="headingAnchor" id="H188957815"><span class="h3">Decision to transfuse</span><span class="headingEndMark"> — </span>Individuals with SCD have a high frequency of serious perioperative complications, some of which may be ameliorated by preoperative red blood cell (RBC) transfusion. The risk versus benefit of no transfusions, conservative transfusions, or aggressive transfusions is unclear for many surgical procedures.</p><p>We agree with recommendations by the 2020 American Society of Hematology (ASH) guidelines on transfusion in SCD, which suggest preoperative transfusion for most patients with SCD undergoing elective surgical procedures requiring general anesthesia and lasting ≥1 hour [<a href="#rid1">1</a>].</p><p>Some individuals may avoid transfusion, such as those with a milder SCD phenotype (eg, Hb SC disease or sickle-beta<sup>+</sup> thalassemia), those with higher baseline Hb F levels (&gt;20 percent of total hemoglobin) due to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or hereditary persistence of fetal hemoglobin (HPFH), or those undergoing minor surgical procedures. For these individuals, decisions regarding preoperative simple transfusion depend on the individual's disease severity. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Monitoring and dose titration'</a> and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes", section on 'Sickle-hereditary persistence of fetal hemoglobin'</a>.)</p><p>Support for the use of perioperative transfusion in most patients with SCD comes from the <strong>T</strong>ransfusion <strong>A</strong>lternatives <strong>P</strong>reoperatively in <strong>S</strong>ickle Cell Disease (TAPS) trial, which randomly assigned 70 children and adults with sickle cell anemia (Hb SS or sickle-beta<sup>0</sup> thalassemia) to no preoperative transfusion or preoperative transfusion with a target hemoglobin level of 10 g/dL [<a href="#rid2">2</a>]. Patients were excluded if they had a hemoglobin concentration &lt;6.5 g/dL, transfusion during the preceding three months, acute chest syndrome within the previous six months, oxygen saturation &lt;90 percent, current dialysis, or a history of stroke in children. The median hemoglobin at entry was 7.7 to 8.0 g/dL, and most patients underwent intermediate-risk surgery. Due to an increased incidence of serious adverse events in the no-transfusion arm, this study was terminated early. Compared with no transfusion, those who received preoperative transfusion had the following benefits [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fewer serious adverse events such as acute chest syndrome or acute pain episodes (3 versus 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>More total units transfused (2.1 versus 1.2 units)</p><p class="bulletIndent1"><span class="glyph">●</span>Similar length of hospital stay</p><p class="bulletIndent1"><span class="glyph">●</span>Lower overall cost of resources</p><p class="bulletIndent1"><span class="glyph">●</span>Alloimmunization in one patient (versus none in the group that was not transfused)</p><p></p><p>This study excluded patients undergoing high-risk surgery such as cardiovascular or intracranial surgery. However, patients undergoing high-risk surgery may receive an additional benefit from prophylactic transfusion and/or a Hb S concentration of &lt;30 percent.</p><p>Preoperative transfusion may not be necessary in patients undergoing brief minor procedures such as myringotomy, cataract extraction, skin biopsies, or other interventions requiring sedation or imaging procedures that require anesthesia. However, some individuals undergoing brief minor procedures may benefit from transfusion, especially if they have a history of surgical complications related to SCD.</p><p>Regardless of whether simple transfusion or exchange transfusion is used (see <a class="local">'Transfusion approach (simple versus exchange)'</a> below), extended crossmatching (ABO; Rh C, D and E; and Kell K antigens) is important in individuals with SCD due to their high risk of alloimmunization. RBC units should also be negative for sickle cell trait. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Transfusion techniques'</a> and  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Alloimmunization and hemolysis'</a>.)</p><p>Risks of alloimmunization and other transfusion risks are discussed separately [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Likelihood of alloimmunization'</a> and  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Risks and complications of transfusion'</a>.)</p><p class="headingAnchor" id="H2877723318"><span class="h3">Transfusion approach (simple versus exchange)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient-related considerations </strong>– For patients with SCD (homozygous Hb SS or Hb S-beta<sup>0</sup> thalassemia) who have a baseline hemoglobin &lt;9 g/dL and are undergoing cardiac or noncardiac surgery lasting ≥1 hour, we recommend preoperative simple transfusion. The goal is to raise the total hemoglobin to approximately 10 g/dL.</p><p></p><p class="bulletIndent1">In an observational study of patients with lower-risk genotypes such as Hb SC disease or Hb S-beta<sup>+ </sup>thalassemia, the incidence of SCD-related complications in the subset of patients undergoing intra-abdominal procedures was significantly higher in patients not transfused prior to their surgery compared with those who were transfused (35 versus 0 percent) [<a href="#rid4">4</a>]. However, available evidence regarding perioperative outcomes is limited for these lower-risk genotypes. Patients who are relatively asymptomatic do not necessarily require preoperative transfusion therapy, with the exception of those undergoing cardiac surgery with CPB. (See <a class="local">'Additional considerations for cardiac surgery with CPB'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure-related considerations </strong>–<strong> </strong>For most patients with Hb SS or Hb S-beta<sup>0</sup> thalassemia who are scheduled to undergo noncardiac surgery lasting ≥1 hour, we suggest simple rather than exchange transfusion. A conservative simple transfusion approach provides equivalent outcomes, similar rates of major complications, and fewer transfusion-related complications relative to exchange transfusion. These findings have been demonstrated in several multicenter cooperative studies performed by the National Preoperative Transfusion in Sickle Cell Disease Study Group [<a href="#rid2">2,5-8</a>].</p><p></p><p class="headingAnchor" id="H2465303845"><span class="h4">Supporting evidence for simple transfusion</span><span class="headingEndMark"> — </span>In a randomized study, 604 patients undergoing various types of surgical procedures were assigned to receive either an aggressive exchange transfusion regimen designed to reduce the Hb S to &lt;30 percent, or a conservative transfusion regimen designed only to increase the Hb concentration to 10 g/dL [<a href="#rid5">5</a>]. The incidence of serious complications (31 and 35 percent) and acute chest syndrome (10 percent) were not different in the two groups. However, the aggressive transfusion group had a higher rate of transfusion-related complications such as alloimmunization (14 versus 7 percent) [<a href="#rid5">5</a>].</p><p>Limited data from patients undergoing specific types of surgical procedures include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthopedic surgery</strong> – Serious surgical complications such as excessive intraoperative blood loss (defined as loss of more than 10 percent of blood volume) occurred in 67 percent of these patients, while 17 percent had SCD-related complications (acute chest syndrome and vaso-occlusive events) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholecystectomy</strong> – SCD-related complications occurred in 19 percent of these patients undergoing cholecystectomy, and those who were not transfused had a higher incidence of such complications (32 percent). However, 10 percent of the patients in this study had transfusion-related complications [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ear, nose, and throat surgery</strong> – Serious complications including SCD-related complications or transfusion-related complications occurred in 32 percent of patients undergoing tonsillectomy and adenoidectomy, and in 36 percent of those undergoing myringotomy [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H3642297551"><span class="h4">Exchange transfusion</span><span class="headingEndMark"> — </span>For selected patients with moderate-to-high risk of vaso-occlusive complications, we suggest partial or full RBC exchange before surgery rather than simple transfusion. Only exchange transfusion is able to reduce the percent Hb S to &lt;30 percent of total hemoglobin without raising the total hemoglobin above 11 g/dL (hemoglobin &gt;11 g/dL is problematic since it increases the risk for hyperviscosity syndrome) [<a href="#rid9">9-14</a>]. Decisions to use exchange transfusion depend on:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient-related considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of stroke, acute chest syndrome, multi-organ failure, or frequent vaso-occlusive pain episodes in the prior year, particularly if Hb S is &gt;30 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior surgical complications related to SCD</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure-related considerations </strong>–<strong> </strong>High risk surgical procedures include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery with CPB – An option for these cases is to perform the RBC exchange in the operating room after cannulation for bypass (see <a class="local">'Additional considerations for cardiac surgery with CPB'</a> below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system surgery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Organ transplant</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major orthopedic surgery (eg, joint replacement for avascular necrosis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Need for emergency surgery during an acute SCD complication such as stroke or acute chest syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with baseline hemoglobin ≥9 g/dL </strong>– Baseline hemoglobin ≥9 g/dL<strong> </strong>is too high to receive simple transfusion due to concerns about hyperviscosity</p><p></p><p class="bulletIndent3">Exchange transfusion (RBC apheresis and replacement with large volumes of donor RBCs) is used to lower the percentage of hemoglobin that is Hb S and/or other variant hemoglobins without substantially raising the total hemoglobin; it can also be used to raise the total hemoglobin if needed. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Exchange blood transfusion'</a>.)</p><p></p><p>If automated RBC apheresis is not available, manual exchange or partial exchange may be used. As an example, 10 mL/kg of blood can be phlebotomized and an equivalent amount of allogeneic RBCs administered (typically, approximately 5 mL/kg of packed RBCs, which have a higher hemoglobin/hematocrit than whole blood). The percent Hb S may not be reduced below 30 percent by partial exchange transfusion. As an example, when partial exchange is used in individuals with Hb SC disease, Hb A &gt;50 percent or Hb S plus Hb C &lt;50 percent are reasonable targets [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3025816021"><span class="h2">Intraoperative management: General considerations</span><span class="headingEndMark"> — </span>Hypovolemia, hypotension, acidosis, hypoxia, hypothermia, vasoconstriction, or the stress response to anesthesia and surgery may lead to sickling with risk of vaso-occlusive episodes [<a href="#rid3">3</a>]. Prolonged or exaggerated deoxygenation of hemoglobin can lead to hemoglobin precipitation with sickling of red cells. Intraoperative strategies to prevent or minimize sickling include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain adequate hydration </strong>– Avoiding hypovolemia is critically important in patients with SCD. However, in those with underlying cardiomyopathy or kidney dysfunction, care is also taken to avoid overhydration. Invasive monitoring may be warranted to assist with decisions regarding fluid management. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Hydration'</a> and  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Hypovolemia'</a> and  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Hypervolemia'</a>.)</p><p></p><p class="bulletIndent1">Although data are limited, there is a concern that normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (NS) may prolong RBC transit times through the capillary system due to increased RBC stiffness [<a href="#rid3">3</a>]. Most centers use hypotonic solutions such as half-NS with dextrose for intravenous maintenance fluid therapy, while using balanced electrolyte solutions for fluid boluses to treat hypovolemia (eg, <a class="drug drug_general" data-topicid="108196" href="/d/drug information/108196.html" rel="external">lactated Ringer</a>’s solution or Plasmalyte) [<a href="#rid3">3,15,16</a>]. (See  <a class="medical medical_review" href="/d/html/14942.html" rel="external">"Intraoperative fluid management", section on 'Crystalloid solutions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain normothermia</strong> – Hypothermia can lead to vasoconstriction with increased risk of sickling. Causes, prevention, and management of hypothermia in the perioperative setting are discussed in detail in a separate topic. In situations where deliberate intraoperative hypothermia is planned (eg, hypothermic CPB), reducing the percentage of Hb S is considered in the preoperative period or before initiation of CPB. (See <a class="local">'Decisions regarding prophylactic preoperative transfusion'</a> above and <a class="local">'Additional considerations for cardiac surgery with CPB'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain adequate mean arterial pressure (MAP) </strong>–<strong> </strong>Maintain MAP within the patient's baseline preoperative range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid use of a tourniquet </strong>–<strong> </strong>Avoid using a tourniquet in all patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid hypoxia </strong>– Maintain peripheral oxygen saturation (SpO<sub>2</sub>) ≥95 percent to minimize risk of venous deoxygenation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid acidosis </strong>– Maintain normal pH (ie, 7.40 to 7.45).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid use of a intraoperative blood salvage with a cell saver machine </strong>– Since the washing process in a cell saver machine may induce hemolysis or sickling of RBCs that contain Hb S, this blood salvage technique is avoided in most patients with SCD [<a href="#rid3">3,10,17-20</a>]. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p></p><p class="headingAnchor" id="H162133440"><span class="h2">Additional considerations for cardiac surgery with CPB</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management before CPB</strong> – Specific strategies that may be employed before CPB for patients with SCD include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exchange transfusion in the operating room </strong>– If circulating Hb S is &gt;30 percent of total hemoglobin, pre-bypass rapid exchange transfusion is performed in the operating room by the perfusionist as CPB is being initiated [<a href="#rid14">14</a>]. This facilitates efficiency of the rapid exchange transfusion process, whether surgery is urgent or routine. This is accomplished by removing a portion of the patient's whole blood (which is discarded), while supplementing blood volume with a mixture of packed RBCs, fresh frozen plasma, albumin, and/or a balanced electrolyte crystalloid solution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other potential modifications</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Use of an autotransfusion device </strong>– Before CPB, an autotransfusion device may be used to separate autologous plasma before CPB [<a href="#rid21">21</a>]. The plasma and clotting factors from the discarded blood can be sequestered using intraoperative plasmapheresis for later reinfusion.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Use of a modified circuit to collect discarded blood</strong> – The perfusionist can modify the CPB circuit to allow a portion of the patient's blood to be collected and discarded during initiation of CPB. Combined with simultaneous infusion of donor blood, this technique will reduce circulating Hb S levels [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management during CPB </strong>– During CPB, control of temperature, oxygenation, and cardiac output (ie, pump flow rate) is managed by the perfusionist. Strategies to maximize tissue oxygen delivery and minimize sickling during CPB include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use a centrifugal CPB pump, rather than a roller pump, to decrease damage to RBCs and risk of hemolysis [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintain a cardiac index that is modestly higher than normal (ie, ≥2.4 L/minute/m<sup>2</sup>) by adjusting pump flow rates (see  <a class="medical medical_review" href="/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Protocols and standards'</a>). If necessary, vasodilators may be administered to avoid hypertension due to the increased flow rate  (<a class="graphic graphic_table graphicRef119750" href="/d/graphic/119750.html" rel="external">table 2</a>). However, sodium <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a> is avoided due to concern that excessive free hemoglobin may be present in patients with SCD and this may lead to the release of cyanide from the nitroprusside molecule [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintain MAP at the higher end of the usual target range of 50 to 80 mmHg (see  <a class="medical medical_review" href="/d/html/103812.html" rel="external">"Management of cardiopulmonary bypass", section on 'Mean arterial pressure targets'</a>). Ideally, this is accomplished without high doses of vasopressor support.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintain a higher-than-normal arterial oxygen tension (PaO<sub>2</sub>) as necessary to target a higher mixed venous oxygen saturation (SvO<sub>2</sub> &gt;80 percent), with monitoring of continuous arterial and venous blood gases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid excessive unintentional hemoconcentration (eg, due to insensible losses) and avoid intentional hemoconcentration with use of hemofiltration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> if necessary to treat acidosis and maintain pH 7.40 to 7.45.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid cold blood cardioplegia which may cause sickling and vaso-occlusion in the coronary arteries [<a href="#rid10">10,25</a>]. Instead, use cold crystalloid cardioplegia either exclusively, or initially before switching to warm blood cardioplegia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimize cooling during CPB except when necessary to perform certain procedures (eg, ascending aortic or arch reconstruction, pulmonary thromboendarterectomy). Lower systemic temperatures have been associated with sickling in vascular organ beds, increased hemolysis, and adverse outcomes in patients with SCD [<a href="#rid26">26,27</a>].</p><p></p><p class="headingAnchor" id="H2560275828"><span class="h2">Postoperative considerations</span><span class="headingEndMark"> — </span>Similar to the intraoperative period, efforts to avoid hypotension, acidosis, hypoxia, vasoconstriction, and venous stasis are continued during the immediate postoperative period. Particular emphasis is placed on the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid or treat hypothermia </strong>–<strong> </strong>Ongoing warming in the post-anesthesia care unit (PACU) or intensive care unit (ICU) is often necessary to prevent hypothermia. (See  <a class="medical medical_review" href="/d/html/94588.html" rel="external">"Perioperative temperature management", section on 'Hypothermia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain oxygenation</strong> – Maintenance of oxygenation and immediate treatment of hypoxia remain critically important during the postoperative period. We maintain SpO<sub>2</sub> ≥95 percent, continuously monitor respiratory rate, and frequently reassess airway patency in extubated patients. After extubation, incentive spirometry and/or other interventions are used to reduce risks for atelectasis and acute chest syndrome for all patients with SCD. (See  <a class="medical medical_review" href="/d/html/94348.html" rel="external">"Respiratory problems in the post-anesthesia care unit (PACU)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manage pain </strong>–<strong> </strong>Pain management is important to minimize distress that may lead to high catecholamine levels causing vasoconstriction or agitation with excessive oxygen consumption that can reduce SvO<sub>2</sub>. Many adults with SCD are treated with chronic opioids for vaso-occlusive episodes. These patients develop high opioid tolerance and require higher doses of opioids for postoperative pain control. Fear of pain in the postoperative period may lead to splinting or atelectasis contributing to hypoxemia or acute chest syndrome. It is important to distinguish vaso-occlusive pain from acute pain due to the surgical incision or other complications such as pulmonary embolus. Consultation with the acute pain management team is typically necessary for patients with chronic pain and chronic use of opioids. (See  <a class="medical medical_review" href="/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control"</a> and  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism (VTE) prophylaxis </strong>– SCD is a hypercoagulable state that confers greatly increased risk of VTE compared with other patients without SCD [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1">For this reason, postoperative VTE prophylaxis is particularly important. Details are discussed in separate topics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/135261.html" rel="external">"Postoperative care after cardiac surgery", section on 'Venous thromboembolism prophylaxis'</a>.)</p><p></p><p class="headingAnchor" id="H1837729806"><span class="h1">SICKLE CELL TRAIT</span><span class="headingEndMark"> — </span>Sickle cell trait (heterozygosity for the sickle cell variant) is generally considered to be a benign carrier condition. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait"</a>.)</p><p>Many people with sickle cell trait are not aware that they carry the variant, either because they have not been tested or were not informed of test results. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Newborn screening'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative considerations </strong>–<strong> </strong>Preoperative screening for sickle cell trait is not uniformly done. It is likely that many individuals with sickle cell trait undergo surgery without having been informed of their sickle cell status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations for CPB – </strong>Although sickle cell trait does not have an impact on major noncardiac surgical cases, case reports have described severe complications during cardiopulmonary bypass (CPB) [<a href="#rid30">30</a>]. However, it is not clear how commonly this occurs, as many individuals with sickle cell trait are unaware that they carry the sickle cell variant and routine screening is not performed. Institution-specific practices may allow testing before elective cardiac surgery with CPB if patients self-identify with a group at increased risk for carrying the sickle cell variant or who are determined to be at increased risk for any reason.</p><p></p><p class="bulletIndent1">For patients who present with known sickle cell trait before elective cardiac surgery with CPB, a hematology consultation is obtained to determine if risks such as high baseline Hb S levels (&gt;30 percent of total hemoglobin) should be managed. In one study of 170 individuals with sickle cell trait (unrelated to perioperative complications), 44 percent had Hb S &gt;38 percent, 54 percent had Hb S between 31 and 38 percent, and 14 percent had Hb S &lt;31 percent [<a href="#rid31">31</a>]. Although data are scant, for selected procedures such as cardiac surgery with hypothermic CPB, preoperative transfusion may be considered if Hb S is &gt;30 percent [<a href="#rid32">32</a>]. (See <a class="local">'Decisions regarding prophylactic preoperative transfusion'</a> above and <a class="local">'Additional considerations for cardiac surgery with CPB'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative considerations </strong>–<strong> </strong>Since risk of venous thromboembolism (VTE) is increased approximately 1.9-fold in patients with sickle cell trait compared with other patients, perioperative VTE prophylaxis warrants special attention. (See  <a class="medical medical_review" href="/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="headingAnchor" id="H2371108147"><span class="h1">THALASSEMIA</span><span class="headingEndMark"> — </span>Thalassemia refers to a group of autosomal recessive genetic hemoglobinopathies in which globin chains are reduced, leading to hemolysis and anemia. Clinical severity depends on the imbalance between alpha and beta globin chains, which in turn depends on the number of globin genes affected. Patients with severe disease can develop increased iron stores, splenomegaly, and other manifestation of hemolysis and extramedullary hematopoiesis. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Overview of subtypes and disease severity'</a>.)</p><p>Common surgical procedures in individuals with thalassemia are splenectomy, cholecystectomy, liver biopsy, and cesarean birth.</p><p class="headingAnchor" id="H3526030565"><span class="h2">Preoperative assessment and optimization</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for other systemic disease </strong>– A thorough preoperative review of the patient's history and complications related to thalassemia is important. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Monitoring and management of disease complications'</a> and  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">The following issues are of particular concern for anesthetic care:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Organ dysfunction</strong> – Clinical manifestations of thalassemia may include heart failure, arrhythmias, kidney or liver dysfunction due to iron overload, and use of certain iron chelation agents. Some individuals may have pulmonary hypertension or restrictive lung disease [<a href="#rid33">33</a>]. The preoperative evaluation may include additional testing depending on the patient's age, clinical condition, and findings on history and physical examination. Cardiovascular status is monitored closely during surgery. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Heart failure and arrhythmias'</a> and  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Pulmonary abnormalities and PH'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skeletal abnormalities</strong> – Deformities of the skull, facial bones, and spine that may accompany thalassemia may increase difficulty with airway management. Anesthesia providers should be prepared for this, especially in individuals with maxillary hyperplasia. Skeletal abnormalities may increase risk of fractures, as well, making regional anesthetic techniques (ie, neuraxial anesthesia and/or peripheral nerve blocks) difficult or impossible. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Skeletal changes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decisions regarding preoperative transfusion </strong>– Preoperative transfusion may be necessary in some cases [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1">Although no specific target hemoglobin has been identified, maintaining a level at the patient's normal baseline is reasonable before, during, and after surgery. Consideration of hemodilution during cardiopulmonary bypass (CPB) can be left to the anesthesia/perfusion team, as it is easy to supplement with allogeneic red blood cell (RBC) units while on CPB. (See <a class="local">'Additional considerations for cardiac surgery with CPB'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy </strong>– Patients undergoing splenectomy should receive immunizations including conjugate pneumococcal vaccination (15 or 20 valent), meningococcal vaccination (Men ACWY and Men B), and haemophilus influenza Type B vaccination (if not previously administered) in sufficient time to elicit an antibody response; this is critical to reduce the risk of post-splenectomy overwhelming infection. (See  <a class="medical medical_review" href="/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Preoperative considerations'</a>.)</p><p></p><p class="bulletIndent1">Also, patients with a prior splenectomy have increased risk for perioperative infection and should have received appropriate vaccinations. (See  <a class="medical medical_review" href="/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a> and  <a class="medical medical_review" href="/d/html/1404.html" rel="external">"Clinical features, evaluation, and management of fever in patients with impaired splenic function"</a>.)</p><p></p><p class="headingAnchor" id="H832574394"><span class="h2">Intraoperative management: General considerations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular monitoring</strong> – In patients with significant cardiopulmonary disease, more intensive cardiovascular monitoring is prudent for major surgical procedures [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Heart failure and arrhythmias'</a> and  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Pulmonary abnormalities and PH'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid intraoperative blood salvage using a cell saver device</strong> – We typically avoid use of a cell saver device because the washing process may induce hemolysis due to increased fragility of RBCs in patients with transfusion dependent thalassemia, particularly beta thalassemia [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7937.html" rel="external">"Surgical blood conservation: Intraoperative blood salvage"</a>.)</p><p></p><p class="headingAnchor" id="H1571682866"><span class="h2">Additional considerations for cardiac surgery with CPB</span><span class="headingEndMark"> — </span>Although data are scant regarding the possibility of increased risk for hemolysis during CPB in patients with thalassemia, the following strategies are prudent [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use a centrifugal CPB pump rather than a roller pump </strong>– Damage to RBCs and risk of hemolysis are less likely with a centrifugal pump compared with a roller pump in patients with increased RBC fragility [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitor closely for hemolysis </strong>– Hemolysis is suspected if pink-tinged urine indicating hemoglobinuria is observed. Also, we send plasma samples to obtain laboratory values for lactate dehydrogenase (LDH) and free hemoglobin levels, although results may be slow to return and comparison to baseline would be essential.</p><p></p><p class="headingAnchor" id="H1758406597"><span class="h2">Postoperative considerations</span><span class="headingEndMark"> — </span>Patients with thalassemia are at high risk for venous thromboembolism (VTE) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Venous thromboembolism'</a>.)</p><p>Patients undergoing splenectomy have a rapid increase in platelet count, with an increased risk of splenic vein thrombosis in the immediate postoperative period, so we recommend early initiation of VTE prophylaxis.</p><p>VTE prophylaxis is essential, particularly early initiation in patients with a previous splenectomy [<a href="#rid38">38</a>]. Information about VTE prophylaxis following surgery is provided separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/135261.html" rel="external">"Postoperative care after cardiac surgery", section on 'Venous thromboembolism prophylaxis'</a>.)</p><p></p><p>Post-splenectomy considerations such as infection prophylaxis, vaccinations, and VTE prophylaxis are presented separately. (See  <a class="medical medical_review" href="/d/html/117640.html" rel="external">"Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'</a>.)</p><p class="headingAnchor" id="H3175678177"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H1458919536"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell disease (SCD)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative</strong> – Consult a multidisciplinary team (hematology, anesthesiology, surgery) to consider procedural risks, disease severity, medications, baseline hemoglobin, percent sickle hemoglobin, transfusion history, and prior surgical and SCD complications, especially:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stroke</p><p class="bulletIndent3"><span class="glyph">-</span>Cardiomyopathy, pulmonary hypertension</p><p class="bulletIndent3"><span class="glyph">-</span>Myocardial infarction</p><p class="bulletIndent3"><span class="glyph">-</span>Acute chest syndrome, asthma, other chronic lung disease</p><p class="bulletIndent3"><span class="glyph">-</span>Kidney or liver dysfunction</p><p class="bulletIndent3"><span class="glyph">-</span>Multi-organ failure</p><p class="bulletIndent3"><span class="glyph">-</span>Pain history, opioid requirements (for adequate pain control) </p><p></p><p class="bulletIndent2">(See <a class="local">'Preoperative assessment and optimization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative transfusion </strong>– Preoperative transfusion reduces surgical complications in selected individuals.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with Hb SS or sickle-beta<sup>0</sup> thalassemia undergoing procedures lasting ≥1 hour, we suggest preoperative transfusion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Decision to transfuse'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with hemoglobin &lt;9 g/dL who are transfused, we suggest simple transfusion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Transfusion approach (simple versus exchange)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For selected high-risk settings, we suggest exchange transfusion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Examples include high-risk patients (prior stroke or SCD-related surgical complications), procedures (cardiac surgery with cardiopulmonary bypass [CPB], organ transplant, major orthopedic surgery), and patients with baseline hemoglobin ≥9 g/dL (to avoid risks of hyperviscosity). (See <a class="local">'Transfusion approach (simple versus exchange)'</a> above.)</p><p></p><p class="bulletIndent2">Extended red blood cell (RBC) matching helps avoid alloimmunization. Blood should be negative for sickle cell trait. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intraoperative </strong>– Vaso-occlusion can be worsened by hypovolemia, hypotension, acidosis, hypoxia, hypothermia, vasoconstriction, stress response, or venous stasis (see <a class="local">'Intraoperative management: General considerations'</a> above):</p><p></p><p class="bulletIndent2">Avoid cell saver (can induce hemolysis) and maintain:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hydration</p><p class="bulletIndent3"><span class="glyph">-</span>Normothermia</p><p class="bulletIndent3"><span class="glyph">-</span>Baseline mean arterial pressure (MAP)</p><p class="bulletIndent3"><span class="glyph">-</span>Peripheral oxygen saturation (SpO<sub>2</sub>) ≥95 percent </p><p class="bulletIndent3"><span class="glyph">-</span>pH 7.40 to 7.45</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac surgery with CPB </strong>– Exchange transfusion can be done in the operating room using a discard cardiotomy reservoir. (See <a class="local">'Additional considerations for cardiac surgery with CPB'</a> above.)</p><p></p><p class="bulletIndent2">In addition to the above, and provided hemolysis is not induced, management includes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest a centrifugal CPB pump rather than a roller pump (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p class="bulletIndent3"><span class="glyph">-</span>Maintain higher CPB flow (cardiac index ≥2.4 L/minute/m<sup>2</sup>, versus 2.2 to 2.4 L/minute/m<sup>2</sup> in individuals without SCD).</p><p class="bulletIndent3"><span class="glyph">-</span>Maintain MAP &gt;60 mmHg using greater than normal CPB flow rates rather than vasopressors.</p><p class="bulletIndent3"><span class="glyph">-</span>Maintain mixed venous oxygen saturation &gt;80 percent.</p><p class="bulletIndent3"><span class="glyph">-</span>Avoid cold blood cardioplegia; use cold <strong>crystalloid</strong> cardioplegia exclusively or before switching to warm blood cardioplegia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative </strong>– Along with the above, ensure adequate:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pain management. (See  <a class="medical medical_review" href="/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control"</a> and  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Venous thromboembolism (VTE)<strong> </strong>prophylaxis. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Incentive spirometry. (See  <a class="medical medical_review" href="/d/html/6970.html" rel="external">"Strategies to reduce postoperative pulmonary complications in adults"</a> and  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Incentive spirometry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle cell trait </strong>– Sickle cell trait does impact noncardiac surgical cases; preoperative screening is individualized. Since severe complications can occur during CPB, a hematology consultation is obtained. (See <a class="local">'Sickle cell trait'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative </strong>– Evaluate for heart failure, pericarditis, arrhythmias, pulmonary hypertension, kidney or liver dysfunction (due to iron overload), and use of certain iron chelators. Preoperative transfusion may be necessary, although no specific target hemoglobin has been identified. Deformities of the skull, facial bones, and spine may increase difficulty with airway management and regional anesthesia. (See <a class="local">'Preoperative assessment and optimization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery with CPB </strong>– Considerations to minimize and detect hemolysis include (see <a class="local">'Additional considerations for cardiac surgery with CPB'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest a centrifugal CPB pump rather than a roller pump (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This decreases hemolysis risk.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Close monitoring for hemolysis (eg, hemoglobinuria, lactate dehydrogenase, free hemoglobin levels).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postoperative </strong>– VTE prophylaxis is essential, particularly in splenectomized patients. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020; 4:327.</a></li><li><a class="nounderline abstract_t">Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013; 381:930.</a></li><li><a class="nounderline abstract_t">Azbell RCG, Lanzkron SM, Desai PC. Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease. Anesth Analg 2023; 136:1107.</a></li><li><a class="nounderline abstract_t">Neumayr L, Koshy M, Haberkern C, et al. Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. Am J Hematol 1998; 57:101.</a></li><li><a class="nounderline abstract_t">Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.</a></li><li><a class="nounderline abstract_t">Vichinsky EP, Neumayr LD, Haberkern C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol 1999; 62:129.</a></li><li><a class="nounderline abstract_t">Waldron P, Pegelow C, Neumayr L, et al. Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. J Pediatr Hematol Oncol 1999; 21:129.</a></li><li><a class="nounderline abstract_t">Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood 1997; 89:1533.</a></li><li><a class="nounderline abstract_t">Raut MS, Khanuja JS, Srivastava S. Perioperative considerations in a sickle cell patient undergoing cardiopulmonary bypass. Indian J Anaesth 2014; 58:319.</a></li><li><a class="nounderline abstract_t">Chabot D, Sutton R. Mitral valve replacement in a patient with sickle cell disease using perioperative exchange transfusion. J Extra Corpor Technol 2008; 40:275.</a></li><li><a class="nounderline abstract_t">Shulman G, McQuitty C, Vertrees RA, Conti VR. Acute normovolemic red cell exchange for cardiopulmonary bypass in sickle cell disease. Ann Thorac Surg 1998; 65:1444.</a></li><li><a class="nounderline abstract_t">Tziomalos K, Garipidou V, Houmpouridou E, et al. Mitral valve reconstruction in a compound heterozygote for sickle cell anemia and hemoglobin Lepore. J Thorac Cardiovasc Surg 2005; 130:932.</a></li><li><a class="nounderline abstract_t">Kamyszek RW, Raval JS, Srinivasan AJ, et al. Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. Transfusion 2019; 59:2622.</a></li><li><a class="nounderline abstract_t">Yousafzai SM, Ugurlucan M, Al Radhwan OA, et al. Open heart surgery in patients with sickle cell hemoglobinopathy. Circulation 2010; 121:14.</a></li><li><a class="nounderline abstract_t">Carden MA, Brousseau DC, Ahmad FA, et al. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. Am J Hematol 2019; 94:689.</a></li><li><a class="nounderline abstract_t">Ojo AS, Ojukwu S, Asmare W, et al. Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis. J Hematol 2022; 11:159.</a></li><li class="breakAll">AMSECT Sickle Cell Disease Clinical Protocol. Available at: https://www.amsect.org/page/perfusion-clinical-resources-1117.</li><li class="breakAll">Gravlee G, Davis R, Kurusz M, Utley J. Cardiopulmonary Bypass Principles and Practice, Lippincott, Philadelphia 2000. p.581.</li><li><a class="nounderline abstract_t">You D, Peiro-Garcia A, Ferri-de-Barros F, Parsons D. Hemolysis Following Intraoperative Cell Salvage Replacement in a Scoliosis Patient With Sickle Cell Trait: A Case Report. Spine (Phila Pa 1976) 2017; 42:E1331.</a></li><li><a class="nounderline abstract_t">Bennett-Guerrero E, Kirby BS, Zhu H, et al. Randomized study of washing 40- to 42-day-stored red blood cells. Transfusion 2014; 54:2544.</a></li><li><a class="nounderline abstract_t">Bocchieri KA, Scheinerman SJ, Graver LM. Exchange transfusion before cardiopulmonary bypass in sickle cell disease. Ann Thorac Surg 2010; 90:323.</a></li><li><a class="nounderline abstract_t">Mullins F, Ott S, Mister N, Travis J. Sickle Cell Hemoglobin C Disease Patient Undergoing Coronary Artery Bypass Grafting with Complete Exchange Blood Transfusion during Cardiopulmonary Bypass. J Extra Corpor Technol 2018; 50:117.</a></li><li><a class="nounderline abstract_t">Hansbro SD, Sharpe DA, Catchpole R, et al. Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, nonocclusive roller pumps and centrifugal pumps. Perfusion 1999; 14:3.</a></li><li><a class="nounderline abstract_t">Cheung AT, Cruz-Shiavone GE, Meng QC, et al. Cardiopulmonary bypass, hemolysis, and nitroprusside-induced cyanide production. Anesth Analg 2007; 105:29.</a></li><li><a class="nounderline abstract_t">Sutton SW, Hunley EK, Duncan MA, et al. Sickle cell disease and aortic valve replacement: use of cardiopulmonary bypass, partial exchange transfusion, platelet sequestration, and continuous hemofiltration. Tex Heart Inst J 1999; 26:283.</a></li><li><a class="nounderline abstract_t">Maddali MM, Rajakumar MC, Fahr J, et al. Cardiopulmonary bypass without preoperative exchange transfusion in sicklers. Asian Cardiovasc Thorac Ann 2006; 14:51.</a></li><li><a class="nounderline abstract_t">Epis F, Chatenoud L, Somaschini A, et al. Simple open-heart surgery protocol for sickle-cell disease patients: a retrospective cohort study comparing patients undergoing mitral valve surgery. Interact Cardiovasc Thorac Surg 2022; 35.</a></li><li><a class="nounderline abstract_t">Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell disease. Blood 2018; 132:1761.</a></li><li><a class="nounderline abstract_t">Brunson A, Lei A, Rosenberg AS, et al. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol 2017; 178:319.</a></li><li><a class="nounderline abstract_t">Ali JM, Besser M, Goddard M, et al. Catastrophic sickling crisis in patient undergoing cardiac transplantation with sickle cell trait. Am J Transplant 2019; 19:2378.</a></li><li><a class="nounderline abstract_t">al-Shakour AA, al-Suhail AA. Percentage of HbS among cases of sickle-cell trait in Basra, Iraq. East Mediterr Health J 2000; 6:233.</a></li><li><a class="nounderline abstract_t">Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108:847.</a></li><li><a class="nounderline abstract_t">Staikou C, Stavroulakis E, Karmaniolou I. A narrative review of peri-operative management of patients with thalassaemia. Anaesthesia 2014; 69:494.</a></li><li><a class="nounderline abstract_t">Desouky OS, Selim NS, El-Bakrawy EM, El-Marakby SM. Biophysical characterization of beta-thalassemic red blood cells. Cell Biochem Biophys 2009; 55:45.</a></li><li><a class="nounderline abstract_t">Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion 2018; 58:1555.</a></li><li><a class="nounderline abstract_t">Botta L, Savini C, Martin-Suarez S, et al. Successful mitral valve replacement in a patient with a severe form of beta-thalassaemia. Heart Lung Circ 2008; 17:77.</a></li><li><a class="nounderline abstract_t">Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol 2012; 5:505.</a></li><li><a class="nounderline abstract_t">Farmakis D, Porter J, Taher A, et al. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere 2022; 6:e732.</a></li></ol></div><div id="topicVersionRevision">Topic 141385 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985807" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352054" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37205803" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462540" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791837" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10539878" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10206459" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057634" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25024478" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Perioperative considerations in a sickle cell patient undergoing cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192758" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mitral valve replacement in a patient with sickle cell disease using perioperative exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9594885" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute normovolemic red cell exchange for cardiopulmonary bypass in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153972" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mitral valve reconstruction in a compound heterozygote for sickle cell anemia and hemoglobin Lepore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31161685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026775" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Open heart surgery in patients with sickle cell hemoglobinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916794" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36406833" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36406833" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36406833" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28441316" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hemolysis Following Intraoperative Cell Salvage Replacement in a Scoliosis Patient With Sickle Cell Trait: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735194" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized study of washing 40- to 42-day-stored red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609818" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Exchange transfusion before cardiopulmonary bypass in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29921991" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sickle Cell Hemoglobin C Disease Patient Undergoing Coronary Artery Bypass Grafting with Complete Exchange Blood Transfusion during Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074641" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, nonocclusive roller pumps and centrifugal pumps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578949" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiopulmonary bypass, hemolysis, and nitroprusside-induced cyanide production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653257" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sickle cell disease and aortic valve replacement: use of cardiopulmonary bypass, partial exchange transfusion, platelet sequestration, and continuous hemofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16432120" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiopulmonary bypass without preoperative exchange transfusion in sicklers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36018254" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Simple open-heart surgery protocol for sickle-cell disease patients: a retrospective cohort study comparing patients undergoing mitral valve surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29764840" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : How I diagnose and treat venous thromboembolism in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369826" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30945451" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Catastrophic sickling crisis in patient undergoing cardiac transplantation with sickle cell trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556007" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Percentage of HbS among cases of sickle-cell trait in Basra, Iraq.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861341" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24601913" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A narrative review of peri-operative management of patients with thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585085" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Biophysical characterization of beta-thalassemic red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29697146" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321216" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Successful mitral valve replacement in a patient with a severe form of beta-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146054" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypercoagulability inβ-thalassemia: a status quo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35928543" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
